COMPANY OVERVIEW

Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. By rapidly developing SLV213 for COVID-19, Selva Therapeutics intends to bring a valuable treatment to the market that has the potential to fight multiple life-threatening infectious diseases. For more info, visit www.selvarx.com.

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

May 31, 2023

Selva Ventures Closes $34 Million Second Fund to Support Emerging Health and Wellness Consumer Brands

Apr 20, 2022

Selva Announces Preclinical Data Confirming SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant

Jul 19, 2021

Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage

Jun 9, 2021

Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern

Feb 2, 2021

Selva Therapeutics Announces Successful Completion of Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19

For More Press Releases

---